Horiguchi J, Iino Y, Takei H, Morishita Y
Department of Surgery, Gunma University School of Medicine, Maebashi.
Jpn J Clin Oncol. 1995 Aug;25(4):119-23.
The expression of c-erbB-2 oncoprotein was studied in relation to the histological type of invasive ductal carcinoma. The expression of c-erbB-2 was found in 26 (17.6%) of 148 cases, and was a significant prognostic indicator in patients with lymph node metastasis, but not in those without. The patients were divided into a scirrhous group and a non-scirrhous group on the basis of histological type. There was no significant difference between the two groups in age, clinical stage, lymph node status, estrogen receptor status, operation method or c-erbB-2 expression. The expression of c-erbB-2 was a significant prognostic indicator in the scirrhous group, irrespective of lymph node metastasis, but not in the non-scirrhous group. We conclude that the prognostic significance of c-erbB-2 expression differs among histological types of invasive ductal carcinoma, and that c-erbB-2 expression is a prognostic indicator in patients with scirrhous carcinoma.
研究了c-erbB-2癌蛋白的表达与浸润性导管癌组织学类型的关系。在148例病例中，有26例（17.6%）发现c-erbB-2表达，其在有淋巴结转移的患者中是一个重要的预后指标，但在无淋巴结转移的患者中则不是。根据组织学类型将患者分为硬癌组和非硬癌组。两组在年龄、临床分期、淋巴结状态、雌激素受体状态、手术方式或c-erbB-2表达方面均无显著差异。c-erbB-2表达在硬癌组中是一个重要的预后指标，无论有无淋巴结转移，而在非硬癌组中则不是。我们得出结论，c-erbB-2表达的预后意义在浸润性导管癌的不同组织学类型中有所不同，并且c-erbB-2表达是硬癌患者的一个预后指标。
